Standard BioTools Inc. (LAB) has a negative trailing P/E of -4.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -21.54%.
Criteria proven by this page:
Overall SharesGrow Score: 51/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -2.8 | -0.07 | 3.97 | 2.02 | - |
| 2017 | -3.2 | 0.11 | 6.28 | 1.91 | - |
| 2018 | -5.8 | 0.30 | 4.74 | 3.03 | - |
| 2019 | -3.6 | 0.10 | 1.51 | 1.98 | - |
| 2020 | -8.2 | 0.34 | 3.11 | 3.13 | - |
| 2021 | -5.0 | -0.93 | 3.14 | 2.28 | - |
| 2022 | -0.5 | 0.00 | -1.12 | 0.94 | - |
| 2023 | -2.3 | 0.04 | -1.18 | 1.65 | - |
| 2024 | -4.4 | 0.10 | 1.31 | 3.54 | - |
| 2025 | -6.5 | 0.11 | 1.15 | 5.72 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-2.62 | $104.45M | $-75.99M | -72.8% |
| 2017 | $-1.84 | $101.94M | $-60.54M | -59.4% |
| 2018 | $-1.49 | $112.96M | $-59.01M | -52.2% |
| 2019 | $-0.97 | $117.24M | $-64.79M | -55.3% |
| 2020 | $-0.74 | $138.14M | $-53.02M | -38.4% |
| 2021 | $-0.78 | $130.58M | $-59.24M | -45.4% |
| 2022 | $-2.43 | $97.95M | $-190.1M | -194.1% |
| 2023 | $-0.94 | $106.34M | $-74.66M | -70.2% |
| 2024 | $-0.52 | $174.43M | $-138.89M | -79.6% |
| 2025 | $-0.20 | $85.33M | $-74.9M | -87.8% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.13 | $-0.13 – $-0.12 | $81.5M | $80.56M – $82.15M | 1 |
| 2027 | $-0.10 | $-0.10 – $-0.10 | $83.6M | $82.63M – $84.26M | 2 |
| 2028 | $-0.09 | $-0.09 – $-0.09 | $87.16M | $85.83M – $88.49M | 1 |
